Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’

Detalles Bibliográficos
Autores principales: Shimokawa, H, Uramoto, H, Tanaka, F
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241566/
https://www.ncbi.nlm.nih.gov/pubmed/21989187
http://dx.doi.org/10.1038/bjc.2011.412
_version_ 1782219531279663104
author Shimokawa, H
Uramoto, H
Tanaka, F
author_facet Shimokawa, H
Uramoto, H
Tanaka, F
author_sort Shimokawa, H
collection PubMed
description
format Online
Article
Text
id pubmed-3241566
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-32415662012-10-25 Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’ Shimokawa, H Uramoto, H Tanaka, F Br J Cancer Letter to the Editor Nature Publishing Group 2011-10-25 2011-10-11 /pmc/articles/PMC3241566/ /pubmed/21989187 http://dx.doi.org/10.1038/bjc.2011.412 Text en Copyright © 2011 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter to the Editor
Shimokawa, H
Uramoto, H
Tanaka, F
Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
title Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
title_full Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
title_fullStr Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
title_full_unstemmed Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
title_short Comment on ‘Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical benefit from figitumumab’
title_sort comment on ‘pre-treatment levels of circulating free igf-1 identify nsclc patients who derive clinical benefit from figitumumab’
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3241566/
https://www.ncbi.nlm.nih.gov/pubmed/21989187
http://dx.doi.org/10.1038/bjc.2011.412
work_keys_str_mv AT shimokawah commentonpretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab
AT uramotoh commentonpretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab
AT tanakaf commentonpretreatmentlevelsofcirculatingfreeigf1identifynsclcpatientswhoderiveclinicalbenefitfromfigitumumab

Ejemplares similares